Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16662
Title: Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma
Austin Authors: Field, Kathryn M;King, Madeleine T;Simes, John;Espinoza, David;Barnes, Elizabeth H;Sawkins, Kate;Rosenthal, Mark A;Cher, Lawrence M ;Hovey, Elizabeth;Wheeler, Helen;Nowak, Anna K
Affiliation: Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Psycho-oncology Co-operative Research Group (PoCoG), School of Psychology and Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
Austin Health, Heidelberg, Victoria, Australia
Prince of Wales Hospital, Barker Street, Randwick, NSW, Australia
Department of Medicine, University of New South Wales, Sydney, NSW, Australia
Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, Australia
Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australia
School of Medicine and Pharmacology, University of Western Australia, 35 Stirling Highway, Crawley, WA, Australia
Issue Date: Jul-2017
metadata.dc.date: 2017-05-22
Publication information: Journal of Neuro-Oncology 2017; 133(3): 623-631
Abstract: In recurrent glioblastoma, health-related quality of life (HRQL) is a crucial trial endpoint. We examined HRQL outcomes as a secondary endpoint for patients in the CABARET randomized phase 2 trial. 122 patients were randomly allocated to bevacizumab monotherapy or bevacizumab plus carboplatin. We calculated change scores from baseline for each HRQL measure on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Brain Cancer Module (QLQ-BN20), together with time to deterioration in HRQL, and the proportion of participants with clinically meaningful improvements in specific disease-related symptoms. At baseline, 117 of 122 randomized patients (96%) attempted questionnaires. Questionnaire participation rates were >90% for patients continuing on treatment, however at the end-of-treatment visit only 72 (64% of eligible participants) returned a form. There were no differences between arms in change scores over the treatment period. Time to ≥10 point deterioration in scores from baseline was also similar between arms. HRQL deterioration occurred largely before progression for the domains tested, but scores in HRQL domains specifically relevant to symptoms of recurrent glioblastoma also improved for about 50% of patients with symptoms at baseline. Neither detrimental nor beneficial effects on HRQL were seen with carboplatin added to bevacizumab, with a proportion of patients on both arms experiencing symptomatic benefit. Given the reduced questionnaire completion at end of treatment, time to HRQL deterioration is a feasible and robust clinical trial endpoint in this patient population. Clinical trials registration number: ACTRN12610000915055.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16662
DOI: 10.1007/s11060-017-2479-8
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28534153
Type: Journal Article
Subjects: BN20
Bevacizumab
Carboplatin
Clinical trial
Glioblastoma
QLQ-C30
Quality of life
Type of Clinical Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.